| 摘要: |
| [摘要]目的：探讨N-甲基-D-天冬氨酸受体2B亚单位基因（GRIN2B）rs1806201位点和rs1805247位点多态性与哌甲酯治疗汉族注意缺陷多动障碍（ADHD）患儿疗效的关系。方法：2017年1月至2019年1月驻马店市中心医院收治的100例ADHD患儿作为研究对象，进行2~4周的哌甲酯开放剂量治疗，获得最佳治疗反应。采用注意缺陷多动障碍诊断量表父母版（ADHDDS-P）评估ADHD症状。根据治疗前后量表评分，将疗效分为缓解、有效和无效。用TaqMan SNP 基因分型技术检测GRIN2B基因rs1806201位点和rs1805247位点多态性。结果：100例患儿治疗后缓解40例，有效25例，无效35例。GRIN2B基因rs1806201位点TT型和CT型患儿治疗效果优于CC型患儿（P<0.05）。而rs1805247位点不同基因型患儿治疗效果的比较差异无统计学意义（P>0.05）。rs1806201位点TT和CT基因型患儿治疗后ADHDDS-P量表注意力缺陷评分、多动冲动评分和总分的减分值均高于CC型患儿（P<0.05），而rs1805247位点不同基因型患儿ADHDDS-P量表减分值比较差异无统计学意义（P>0.05）。结论：GRIN2B基因rs1806201位点多态性与哌甲酯治疗效果有关，而GRIN2B基因rs1805247位点多态性与哌甲酯治疗效果无关。GRIN2B基因rs1806201位点TT型和CT型ADHD患儿对哌甲酯的药物反应优于CC基因型患儿。 |
| 关键词: N-甲基-D-天冬氨酸受体2B亚单位基因 注意缺陷多动障碍 哌甲酯 基因多态性 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2020.05.011 |
|
| 基金项目: |
|
| Correlation between Efficacy of Methylphenidate in the Treatment of Attention Deficit Hyperactivity Disorder and GRIN2B Gene Polymorphism in Children in Han Nationality |
| Zhou Jing, Li Hongye, Kong Yonghong |
| (Zhumadian Central Hospital, Henan Zhumadian 463000, China) |
| Abstract: |
| [Abstract] Objective: To probe into the correlation between the polymorphism of N-methyl-D-aspartate receptor 2B (GRIN2B) rs1806201 and rs1805247 locus and efficacy of methylphenidate in the treatment of attention deficit hyperactivity disorder (ADHD) in children in Han nationality. Methods: Totally 100 children with ADHD admitted into Zhumadian Central Hospital from Jan. 2017 to Jan. 2019 were extracted to be treated with open-dose of methylphenidate for 2 to 4 weeks, so as to obtain the best therapeutic response. ADHD symptoms were assessed with the Attention Deficit Hyperactivity Disorder Diagnostic Scale Parent Version (ADHDDS-P). According to the scale score before and after treatment, the clinical efficacy was divided into remission, effectiveness, and inefficiency. TaqMan SNP genotyping technique was used to detect the polymorphism at rs1806201 and rs1805247 locus of GRIN2B gene. Results: After treatment, 40 cases were relieved, 25 cases were effective and 35 cases were ineffective. The clinical efficacy of TT and CT genotypes at rs1806201 locus of GRIN2B gene was better than that of CC genotype (P<0.05). However, there was no significant difference in the clinical efficacy of different genotypes of rs1805247 locus (P>0.05). After treatment, the attentional deficit score, hyperactivity impulse score and total score of ADHDDS-P in children with TT and CT genotypes at rs1806201 locus were higher than those in children with CC genotype (P<0.05), while there was no significant difference in the deduction score of ADHDDS-P among children with different rs1805247 locus (P>0.05). Conclusion: The polymorphism of rs1806201 of GRIN2B gene is related to the clinical efficacy of methylphenidate, while polymorphism of rs1805247 of GRIN2B gene is not correlated with efficacy of methylphenidate. The TT and CT genotypes at rs1806201 locus of GRIN2B gene in children in Han nationality had better drug response to methylphenidate than CC genotype. |
| Key words: N-methyl-D-aspartate receptor 2B attention deficit hyperactivity disorder methylphenidate gene polymorphism |
